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Abstract
Background:  The calcium sensing receptor (CaSR) regulates serum calcium by suppressing
secretion of parathyroid hormone; it also regulates renal tubular calcium excretion. Inactivating
mutations of CaSR raise serum calcium and reduce urine calcium excretion. Thyroid C-cells (which
make calcitonin) express CaSR and may, therefore, be regulated by it. Since calcium stimulates
release of calcitonin, the higher blood calcium caused by inactivation of CaSR should increase
serum calcitonin, unless CaSR mutations alter the responsiveness of calcitonin to calcium.
To demonstrate regulatory effects of CaSR on calcitonin release, we studied calcitonin
responsiveness to calcium in normal and CaSR heterozygous-ablated (Casr+/-) mice. Casr+/- mice
have hypercalcemia and hypocalciuria, and live normal life spans. Each mouse received either 500
µl of normal saline or one of two doses of elemental calcium (500 µmol/kg or 5 mmol/kg) by
intraperitoneal injection. Ionized calcium was measured at baseline and 10 minutes, and serum
calcitonin was measured on the 10 minute sample.
Results: At baseline, Casr+/- mice had a higher blood calcium, and in response to the two doses of
elemental calcium, had greater increments and peak levels of ionized calcium than their wild type
littermates. Despite significantly higher ionized calcium levels, the calcitonin levels of Casr+/- mice
were consistently lower than wild type at any ionized calcium level, indicating that the dose-
response curve of calcitonin to increases in ionized calcium had been significantly blunted or shifted
to the right in Casr+/- mice.
Conclusions: These results confirm that the CaSR is a physiological regulator of calcitonin;
therefore, in response to increases in ionized calcium, the CaSR inhibits parathyroid hormone
secretion and stimulates calcitonin secretion.
Background
Ionized calcium concentration of extracellular fluid is
tightly regulated, subject to minute-to-minute control in
order to maintain such diverse processes as cell mem-
brane integrity, neuromuscular transmission and blood
coagulation [1]. Small decreases in ionized calcium
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provoke excitability of the nervous system that can mani-
fest as paresthesias and seizures; in contrast, increases in
ionized calcium dampen nervous system responses and
lead to such manifestations as constipation, obtundation,
and coma. Parathyroid hormone (PTH) and calcitonin
have long been recognized to respond quickly (but in
opposite directions) to increases or decreases in ionized
calcium [1-3].
The "homeostat" that controls ionized calcium has been
recognized to be the calcium sensing receptor (CaSR), a G
protein-coupled, seven transmembrane-spanning recep-
tor that binds calcium ions [4]. CaSR mRNA and protein
are expressed by parathyroid chief cells that produce PTH.
Binding of calcium activates the CaSR; consequently, an
increase in ionized calcium leads to more activation of the
receptor and, thereby, inhibition of PTH secretion. Con-
versely, a fall in ionized calcium leads to less activation of
the receptor, and PTH escapes from inhibitory control. In
the long-term, the CaSR also regulates the growth of par-
athyroid cells and the synthesis of PTH.
Since the original cloning of the CaSR by Dr. Edward
Brown and colleagues at Harvard [5], it has been recog-
nized that CaSR mRNA is also expressed by the C-cells of
the thyroid, the source of calcitonin [6]. Furthermore,
cells from a medullary thyroid carcinoma cell line express
CaSR mRNA and release calcitonin in response to calcium
[7]. The presence of the CaSR on C-cells raises the possi-
bility that the CaSR might directly regulate calcitonin
release; however, Dr. Brown has noted that the presence
of the CaSR in a cell whose function is modulated by cal-
cium is not sufficient proof that the CaSR mediates that
particular action of calcium [4].
The regulation of calcitonin is opposite to that of PTH, in
that increases in ionized calcium stimulate calcitonin, and
decreases in ionized calcium lead to a fall in calcitonin.
This observation led to the general assumption that the
mechanisms mediating calcium sensing in parathyroid
and C cells are distinctly different, with the latter likely
involving some form of voltage-sensitive calcium chan-
nels [4,8]. It was, therefore, somewhat unexpected that the
parathyroid CaSR would turn out to be expressed by C
cells of the thyroid. Because calcium is the primary stimu-
lus for changes in calcitonin, and the C cells express the
CaSR, the CaSR is a logical and obvious candidate to fulfill
the homeostatic regulatory function that it also does for
PTH [4,8,9].
To address the issue of a role for the CaSR in regulating
calcitonin in vivo, we utilized the calcium receptor gene
ablation model [10]. Heterozygous (Casr+/-) mice have
increased ionized calcium, modest hyperparathyroidism,
and reduced renal calcium excretion. Homozygous (Casr
null) mice have severe hypercalcemia and hyperparathy-
roidism, and die within several weeks of birth. These two
conditions mimic the corresponding human conditions
in which CaSR function is impaired or absent, respectively
familial hypocalciuric hypercalcemia and neonatal severe
hypercalcemia [5].
We addressed the hypothesis that the CaSR stimulates cal-
citonin release in response to an increase in the blood cal-
cium concentration. Thus, in Casr+/- mice, we expected to
see that the calcitonin response to an increase in blood
calcium would be blunted compared to the normal
response, or shifted to the right. This is in fact what was
observed.
Results
It was anticipated that provoking a calcitonin response by
calcium injection would demonstrate that ablation of the
CaSR had altered the normal relationship between ion-
ized calcium and calcitonin levels. Such an experiment
was not practical in fetuses because 3–4 fetal samples
would have to be pooled for each calcitonin measure-
ment. Instead, adults were used so that larger blood sam-
ples suitable for assay would be obtained. This meant that
only wild type and Casr+/- mice could be studied, because
Casr null mice are visibly ill within days of birth and die
by two to three weeks of age.
Casr+/- mice had higher ionized calcium levels at baseline
compared to wild type, consistent with the known pheno-
type of these mice in both the original C57BL/6 back-
ground [10] and in the Black Swiss background [11]. The
saline injection did not significantly alter ionized calcium,
although the mean value dropped for both wild type and
Casr+/- mice, and appeared to be proportionately greater
for Casr+/- mice (Table 1). The two different doses of cal-
cium resulted in significant elevations in ionized calcium
(Table 1) compared to baseline and compared to the
effect of the saline injection. Casr+/- mice had proportion-
ately greater increments in ionized calcium and reached
higher peak ionized calcium levels as compared to wild
type. Thus, the higher baseline ionized calcium, the
greater increments in ionized calcium, and the higher
peak values in ionized calcium achieved by Casr+/- mice
biased the experiment in favour of obtaining a higher
peak calcitonin response from Casr+/- as compared to wild
type.
The mean baseline (post-saline) serum calcitonin levels
were slightly lower in Casr+/- mice as compared to wild
type, at 12.1 ± 8.0 versus 20.4 ± 8.9 pg/ml, respectively (p
= 0.49). In response to calcium injection, the calcitonin
level rose in wild type and Casr+/- mice as expected (Figure
1). A logarithmic scatterplot of the data in Figure 1A dem-
onstrates that Casr+/- mice achieved lower calcitonin levelsBMC Physiology 2004, 4 http://www.biomedcentral.com/1472-6793/4/5
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for each level of ionized calcium, and regression analysis
confirmed that the dose-response curve for calcitonin was
shifted significantly to the right in Casr+/- mice. The mean
(± SE) data are plotted in Figure 1B, and confirm shift of
calcitonin responsiveness in Casr+/- mice.
Discussion
These observations in adult wild type and Casr+/- mice
demonstrate a definite shift in the physiological response
of calcitonin to acute increments in ionized calcium. Since
this response was dependent upon the genotype (wild
type versus Casr+/-), it is clear that ablation of the CaSR
was the determinant that shifted calcitonin responsive-
ness. The "shift to the right" in calcitonin responsiveness
between wild type and Casr+/- mice confirms that the CaSR
is a physiological regulator of calcitonin release. These
observations complement and confirm the earlier obser-
vations of Lavigne et al, who demonstrated that the cal-
Table 1: Mean (± SE) ionized calcium levels before (pre) and after (post) injection in wild type and Casr+/- mice. P values apply to the 
comparison of respective post versus pre values, and to the post values versus the corresponding post-saline value.
Genotype Injection Pre Post p value
Wild type Saline (16) 1.28 ± 0.03 1.26 ± 0.02 -
Wild type 500 µmol/kg (13) 1.29 ± 0.02 1.34 ± 0.04 < 0.01
Wild type 5 mmol/kg (8) 1.29 ± 0.02 1.55 ± 0.06 < 0.01
Casr+/- Saline (20) 1.42 ± 0.02 1.34 ± 0.04 -
Casr+/- 500 µmol/kg (25) 1.42 ± 0.02 1.50 ± 0.02 < 0.01
Casr+/- 5 mmol/kg (23) 1.40 ± 0.01 1.71 ± 0.03 < 0.01
Blunted calcitonin responsiveness in Casr+/- mice Figure 1
Blunted calcitonin responsiveness in Casr+/- mice. On the left (1A), a logarithmic scatterplot of serum calcitonin versus ionized 
calcium level in wild type and Casr+/- mice. The straight lines indicate the respective best-fit regression lines; the respective 95% 
confidence intervals for the fitted lines are also shown, and have been demarcated by double-headed arrows for easier recog-
nition. On the right (1B), a normal plot of mean serum calcitonin (± SE) versus mean ionized calcium (± SE) in wild type and 
Casr+/- mice. Vertical SE bars correspond to the calcitonin values, and horizontal error bars correspond to ionized calcium val-
ues. The peak calcitonin response of wild type and Casr+/- was significantly different for both ionized calcium and calcitonin (p < 
0.02). In both graphs, the closed squares indicate wild type values, and the open squares indicate Casr+/- values.
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cimimetic compound NPS R-467 stimulates calcitonin
release in rats [12]. NPS R-467 activates the CaSR and
suppresses PTH release; it was reasonably inferred from
those experiments that NPS R-467 was stimulating the
release of calcitonin through direct actions on the CaSR.
The possibility that calcitonin was not stimulated directly
by NPS R-467 could not be completely excluded in those
experiments, and thus, our experiments in Casr+/- mice
provide physiological evidence that the calcitonin
response is dependent upon the CaSR.
The effect of inactivating mutations of the CaSR on serum
calcitonin in humans has not been extensively or rigor-
ously examined, apart from noting that individuals with
hypercalcemia due to familial hypocalciuric hypercal-
cemia (FHH) had apparently normal baseline calcitonin
levels using older calcitonin radioimmunoassays [13-15].
In the first study [13], baseline calcitonin levels in 12 indi-
viduals with FHH were no different than in 9 unaffected
individuals from the same kindred. In the second study
[14], no calcitonin measurements were obtained from
normal or unaffected individuals, but instead the results
of FHH individuals were simply reported as being within
the (at the time) wide normal range of < 69 pg/ml. In the
third cited study, the baseline calcitonin levels in 26 indi-
viduals with FHH were compared to 20 unrelated healthy
controls. The lack of a difference in baseline serum calci-
tonin levels in all three of these studies is similar to our
observation that, at baseline, the calcitonin levels in Casr+/
- mice are slightly lower but not significantly different than
in related wild type mice. The presence of hypercalcemia
at baseline in both Casr+/- mice and in patients with FHH
should have caused a higher calcitonin level if the CaSR
had normal sensitivity to calcium and normal function. It
is only with the calcium challenge that the blunted calci-
tonin responsiveness became definitively apparent in our
studies of Casr+/- mice. A 5 minute calcium challenge with
calcitonin response was performed in only one of the
studies in humans with FHH but was reported to show no
difference in calcitonin response compared to unrelated
normal controls [15]. Interestingly, in that study the mean
results were actually lower in affected individuals, being
33.6 ± 7.0 pg/ml in 7 normal males versus 18.6 ± 5.4 pg/
ml in 6 affected males with FHH, and 9.8 ± 5.4 pg/ml in
7 normal females versus 7.9 ± 2.7 pg/ml in 7 affected
females with FHH. Thus, the low sample size number is
likely a key reason why that study did not demonstrate
these apparent differences to be statistically significant.
That study, performed more than 13 years ago, may also
have failed to demonstrate a difference due to the earlier-
generation calcitonin assay used, and the heterogeneity of
the patients under study (unrelated controls) as compared
to the current study that used genetically related mice. The
possibility of a species difference cannot be excluded; that
is, that the CaSR is a significant regulator of calcitonin
release in mice but not in humans.
An alternative explanation for our findings is that chronic
hypercalcemia in Casr+/- mice downregulated the respon-
siveness of calcitonin through indirect effects, such as by
downregulation of another calcium sensor that in turn
might regulate calcitonin. As shown in Table 1, the Casr+/
- mice normally maintain a 0.1 mmol/l higher ionized cal-
cium concentration than in wild-type, but acutely
achieved a peak increment in ionized calcium that was
approximately 0.4 mmol/l higher than the post-saline
value. Therefore, because the acute stimulus (increase in
ionized calcium) was much greater than the chronic stim-
ulus (mild hypercalcemia), it is likely that the blunted cal-
citonin response is specific to heterozygous ablation of
the CaSR, and not due to chronic hypercalcemia.
Our current findings that ablation of the CaSR shifts the
responsiveness of calcitonin to acute changes in the serum
calcium predicts that the CaSR will be coupled to different
signal transduction pathways depending upon the tissue
in which it is expressed. In that way, the same receptor can
have an inhibitory response to its activation in parathy-
roid cells, but a stimulatory response to its activation in
parafollicular cells of the thyroid.
Casr+/- mice had greater increments in ionized calcium in
response to the same dose of calcium given to wild type
mice. The slightly greater (but statistically insignificant)
drop in ionized calcium provoked by saline injection in
Casr+/- mice may indicate a difference in intravascular vol-
ume that was not apparent by the normal hematocrit and
body weight that Casr+/- mice have as compared to their
siblings [10](and data not shown). Alternatively, the
blunted calcitonin response of Casr+/- mice may in turn
lead to loss of effect of calcitonin to promote calciuresis
and minimize increases in the blood calcium. The role of
calcitonin to minimize increases in the blood calcium in
response to a calcium or PTH challenge has been demon-
strated in mice lacking calcitonin through a genetic abla-
tion [16]; and in rats rendered calcitonin deficient
through surgical or immunological techniques [17,18].
The renal tubular action of the CaSR may also partly
account for the greater calcemic response of Casr+/- mice.
Casr+/- mice have reduced renal calcium excretion due to
ablation of the CaSR [10,11], and thereby would be
expected to have an impaired ability to excrete calcium in
response to a calcium load. Furthermore, PTH-mediated
bone resorption is increased in Casr+/- mice, which indi-
cates that efflux of calcium from bone is increased, and
bone matrix will be less able to take up calcium in
response to a calcium load [10,11].BMC Physiology 2004, 4 http://www.biomedcentral.com/1472-6793/4/5
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Although calcitonin has often been considered to be a ves-
tigial hormone with no certain role in mammalian cal-
cium and bone homeostasis, this study demonstrates that
calcitonin is subject to physiological regulation by the
CaSR. Recent studies in mice indicate that calcitonin has
important roles in calcium and bone homeostasis that
have not been previously recognized. Mice lacking the
gene encoding calcitonin and calcitonin gene-related pep-
tide-α (CGRP-α) develop a phenotype of increased bone
mass as adults [16], a phenotype that is not present at the
end of fetal development [19]. Mice that are heterozygous
for loss of the calcitonin receptor also have a phenotype of
increased bone mass as adults [20]. Preliminary studies
have indicated that mice lacking the gene encoding calci-
tonin and CGRP-α lose more than twice as much skeletal
calcium content as their wild-type sisters during three
weeks of lactation [21], confirming a previously postu-
lated role that calcitonin might protect the maternal skel-
eton from excessive resorption during lactation. Thus,
calcitonin has new and emerging evidence of its impor-
tance in regulating calcium homeostasis and bone mass.
It may be inferred that the CaSR regulates bone mass
through its effect on the parathyroid glands to produce
PTH, and through its effect on C-cells of the thyroid to
produce calcitonin. In the short-term, the CaSR regulates
ionized calcium concentration in blood by altering the
release of PTH and calcitonin; in the long-term, it influ-
ences the maintenance of bone mass through these same
hormones. In the future, pharmacological agents that can
manipulate the CaSR to achieve an ideal balance of calci-
tonin and PTH in the circulation may provide a novel
approach to treating disorders such as osteoporosis, sec-
ondary (uremic) hyperparathyroidism, hypercalcemia,
and hypocalcemia [22,23].
Conclusions
In summary, we found that in adult wild type and Casr+/-
mice an acute calcium injection stimulated the release of
calcitonin, but the response curve was blunted or shifted
to the right in Casr+/- mice. We have confirmed that the
CaSR stimulates calcitonin release in response to an
increase in the blood calcium concentration. Therefore,
the CaSR has a dual physiological response to acute
increases in ionized calcium, which includes inhibition of
PTH release and stimulation of calcitonin release. In the
long-term, the actions of the CaSR to regulate PTH and
calcitonin will influence the maintenance of skeletal min-
eral content.
Methods
Casr mice
Casr-ablated mice were the gift of Jon Seidman (Harvard)
and were obtained by targeted disruption of the murine
Casr gene in stem cells, as previously described [10]. The
mice were back-crossed into outbred Black Swiss strain
(Taconic Labs) for at least five generations. Adult wild
type and Casr+/- mice were used that were all first degree
relatives of each other, and between 2 to 4 months of age.
All mice were given a standard chow diet (1% calcium)
and water. All studies were performed with the prior
approval of the Animal Care Committee of Memorial
University of Newfoundland.
Calcium challenge experiments
105 adult mice (37 wild type and 68 Casr+/-) were weighed
and distributed into tertiles, to be given an intraperitoneal
injection of either 500 µl of normal saline (0.9% sodium
chloride), or one of two doses of elemental calcium (500
µmol/kg or 5 mmol/kg in 500 µl of normal saline). These
doses of elemental calcium had been determined in pre-
liminary experiments to result in significant increases in
ionized calcium and calcitonin of both wild type and
Casr+/- mice. Saline injection was used as the control group
in order to control for alterations in ionized calcium that
would occur due to the injection of fluid in the perito-
neum and due to any stress on the animal caused by the
experimental procedure. Tail blood was obtained at base-
line and 10 minutes after the injection of elemental cal-
cium to assay ionized calcium. Whole blood (near total
blood volume) was obtained at 10 minutes by intracar-
diac needle for the calcitonin assay. The two separate
blood collections (tail blood and intracardiac puncture)
were performed at the 10 minute time point in order that
the 10 minute ionized calcium measurements would be
comparable to the baseline ionized calcium measure-
ments. Tail blood and intracardiac blood do not provide
comparable ionized calcium levels.
Assays
Ionized calcium was measured with a specific calcium ion
electrode (Chiron 634 Ca++/pH Analyzer). Serum calci-
tonin was measured in duplicate using a specific IRMA for
rat calcitonin that cross-reacts with murine calcitonin
(Immutopics, San Clemente, CA) [12], and which has pre-
viously been validated in our laboratory for use on mouse
serum [11,24]. In lieu of mouse calcitonin standards, val-
ues were expressed as pg-equivalents rat calcitonin/ml; the
stated detection limit of the assay was 1.0 pg/ml.
Statistical analysis
Data was analyzed using SYSTAT 5.2.1 for Macintosh
(SYSTAT Inc, Evanston, IL). Two-tailed probabilities are
reported, and all data are presented as mean ± SE.
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FHH Familial hypocalciuric hypercalcemia
SE standard error
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